KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedData quality warningStale data
Data as of Oct 26, 2026, 10:36 AM UTC · policy pm-quality-4
Selected book midpoint
Above 8% · —
Loading selected book…
—
Stored price
Above 10.5% 41%Market line of 9 lines
Above 10.5% 41%Market quality
21 / 100
Low quality24h Volume
—
Open interest
$2.4K
Low open interestBid / Ask
— / —
Above 8%Spread
—
Market data
Updated 1 hour ago
LaggingSep 9, 26, 2:00 AM UTCMar 31, 27, 5:00 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Above 8%
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Medtronic cardiovascular organic growth in fiscal 2027
KalshiWill 3 mg THC beverages be federally legal to sell?
KalshiWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill Aurelia Song abandon Nectome before 2041?
Manifold MarketsWhich fast food chain in the USA will offer a lab-grown / cultivated meat product first?
Manifold MarketsWill an AI Labor Shock Crash Markets by 2035?
Manifold MarketsRules
If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
Settles via:Fiscal.ai
- Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company. All trademarks, logos, and brand names are the property of their respective owners.
Rules for each outcome
- Above 8%
- If Medtronic plc reports Above 8% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 9%
- If Medtronic plc reports Above 9% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 10%
- If Medtronic plc reports Above 10% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 10.5%
- If Medtronic plc reports Above 10.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 11%
- If Medtronic plc reports Above 11% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 11.5%
- If Medtronic plc reports Above 11.5% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 12%
- If Medtronic plc reports Above 12% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 13%
- If Medtronic plc reports Above 13% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
- Above 14%
- If Medtronic plc reports Above 14% cardiovascular organic revenue growth in Q2 2027, then the market resolves to Yes.
